WDH Stock Chart & Stats
€19.00
€0.30(1.62%)
At close: 4:00 PM EDT
€19.00
€0.30(1.62%)
Day’s Range― - ―
52-Week Range€11.60 - €24.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.93B
Enterprise Value€11.45B
Total Cash (Recent Filing)€1.50B
Total Debt (Recent Filing)€20.28B
Price to Earnings (P/E)47.0
Beta0.72
Next Earnings
Feb 09, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.73
Shares Outstanding423,506,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)4.48
Price to Sales (P/S)1.92
P/FCF Ratio13.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And OutlookBroad-based revenue expansion, supported by organic growth and acquisitions, indicates continued demand for Demant’s hearing healthcare offerings. The upgraded outlook provides a durable basis for investment in products, distribution and clinics over the coming quarters.
Premium Product Innovation And Market MomentumProduct innovation and premium positioning can support market share, average selling prices and customer retention in hearing aids. Oticon Zeal’s momentum and Oticon Reveal’s differentiated technology strengthen Demant’s competitive proposition beyond temporary demand fluctuations.
Healthy Cash Generation And Cost SavingsPositive operating cash flow gives Demant resources to fund product development, integration and debt reduction. The higher savings target could also improve underlying profitability over time, partly offsetting investment needs and supporting more disciplined capital allocation.
Bears Say
Elevated LeverageThe more debt-heavy capital structure reduces financial flexibility and increases sensitivity to weaker earnings or higher financing costs. Remaining above the leverage target may constrain acquisitions, investment and shareholder distributions until balance-sheet capacity improves.
Lower Operating And Net MarginsMargin compression means rapid sales growth is converting into less profit, weakening earnings quality and operating leverage. If higher costs, mix pressure or one-offs persist, Demant may have less capacity to absorb competitive pricing and fund innovation from internal earnings.
Regional And Competitive Execution PressureWeakness in important regions and a crowded product-launch cycle could make growth less consistent across Demant’s markets. Competitive launches may require additional marketing or pricing support, creating a lasting risk to share gains, margins and the reliability of guidance.
Demant News
WDH FAQ
What was Demant’s price range in the past 12 months?
Demant lowest stock price was €11.60 and its highest was €24.00 in the past 12 months.
What is Demant’s market cap?
Demant’s market cap is €9.93B.
When is Demant’s upcoming earnings report date?
Demant’s upcoming earnings report date is Feb 09, 2027 which is in 110 days.
How were Demant’s earnings last quarter?
Demant released its earnings results on Aug 11, 2026. The company reported €0.38 earnings per share for the quarter.
Is Demant overvalued?
According to Wall Street analysts Demant’s price is currently Overvalued.
Does Demant pay dividends?
Demant does not currently pay dividends.
What is Demant’s EPS estimate?
Demant’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Demant have?
Demant has 423,506,600 shares outstanding.
What happened to Demant’s price movement after its last earnings report?
Demant reported an EPS of €0.38 in its last earnings report. Following the earnings report the stock price went down -1.075%.
Which hedge fund is a major shareholder of Demant?
Currently, no hedge funds are holding shares in DE:WDH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Demant Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.56%
12-Months-Change
Fundamentals
Return on Equity
15.31%
Trailing 12-Months
Asset Growth
19.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Demant
Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.
WDH Company Deck
WDH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong operational and financial positives: robust reported revenue growth (15%), gross profit expansion (+17%) and gross margin improvement (+1.1 ppt), solid cash generation, successful commercial momentum driven by Oticon Zeal and the new Oticon Reveal product positioning, and upgraded full-year guidance. Offsetting these positives are elevated and increased special items tied to acquisitions and restructurings, FX headwinds, regional softness (notably China and managed care in the U.S.), and the risk of competitive launches in H2. On balance, the company’s financial performance, product momentum, successful integration progress and strengthened outlook outweigh the headwinds and one-off costs.View all DE:WDH earnings summariesTechnical Analysis
Dexcom
―
Koninklijke Philips
―
Zimmer Biomet Holdings
―
Envoy Medical
―
GE Healthcare Technologies Inc
―